Monday, May 1, 2000
Shire looks (far) East
Shire Pharmaceuticals Group plc is looking to build in the Pacific Rim
and continental Europe to maintain its revenue and profits growth. Speaking after the
company announced year-on-year revenue growth of 25 percent at $119 million for the first
quarter, CEO Rolf Stahel told BioCentury that he will establish distributorships through
most of the Asia Pacific region but wants to lay down a corporate presence in Japan.
Shire (LSE:SHP; SHPGY, Andover, U.K.) derives only $4.8 million of its
revenues from sales outside the U.S., the U.K. and Ireland.